Literature DB >> 2765437

Penetration of 2% cyclosporin eyedrops into human aqueous humour.

M Diaz-Llopis1, J L Menezo.   

Abstract

The penetration into the eye and the systemic absorption of 2% cyclosporin eye drops were determined by polarisation immunofluorescent assay of cyclosporin in the aqueous humour and plasma of 30 patients at the time of cataract surgery. The results were then compared with the corresponding results after oral administration at a dosage of 5 mg/kg/day to three further patients. The maximum intraocular concentration (24 (SD 9) mg/l) was achieved four hours after topical administration. This level was slightly less than that found in aqueous humour (28 (SD 10) mg/l) 12 hours after systemic administration of the drug at a dosage of 5 mg/kg/day. Both these levels are below the minimum therapeutic level (50-100 mg/l). Topical application of cyclosporin A did not produce detectable levels in plasma at any time. These results indicate that the efficacy of cyclosporin A in the control of intraocular inflammation is attributable to its systemic immunoregulatory effect rather than to the local ocular effect.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2765437      PMCID: PMC1041825          DOI: 10.1136/bjo.73.8.600

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  11 in total

1.  Local cyclosporine therapy for experimental autoimmune uveitis in rats.

Authors:  R B Nussenblatt; W J Dinning; L S Fujikawa; C C Chan; A G Palestine
Journal:  Arch Ophthalmol       Date:  1985-10

2.  Penetration of topical cyclosporine into the rabbit cornea, aqueous humor, and serum.

Authors:  M W Mosteller; B M Gebhardt; A M Hamilton; H E Kaufman
Journal:  Arch Ophthalmol       Date:  1985-01

3.  Differential effects of cyclosporin-A on lymphocyte subpopulations.

Authors:  S B Leapman; R S Filo; E J Smith; P G Smith
Journal:  Transplant Proc       Date:  1981-03       Impact factor: 1.066

4.  A placebo-controlled blind trial of cyclosporin-A in prevention of corneal graft rejection in rabbits.

Authors:  T A Bell; D L Easty; K G McCullagh
Journal:  Br J Ophthalmol       Date:  1982-05       Impact factor: 4.638

5.  Corneal graft rejection: a new rabbit model and cyclosporin-A.

Authors:  P A Hunter; A Garner; K R Wilhelmus; N S Rice; B R Jones
Journal:  Br J Ophthalmol       Date:  1982-05       Impact factor: 4.638

6.  Cyclosporin A: tissue levels following topical and systemic administration to rabbits.

Authors:  T A Bell; A G Hunnisett
Journal:  Br J Ophthalmol       Date:  1986-11       Impact factor: 4.638

7.  Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents.

Authors:  R B Nussenblatt; A G Palestine; C C Chan
Journal:  Am J Ophthalmol       Date:  1983-09       Impact factor: 5.258

8.  Suppression of corneal allograft rejection by cyclosporin A.

Authors:  J D Salisbury; B M Gebhardt
Journal:  Arch Ophthalmol       Date:  1981-09

Review 9.  Cyclosporine: immunology, pharmacology and therapeutic uses.

Authors:  R B Nussenblatt; A G Palestine
Journal:  Surv Ophthalmol       Date:  1986 Nov-Dec       Impact factor: 6.048

10.  Rabbit corneal allograft survival following topical administration of cyclosporin A.

Authors:  J S Kana; F Hoffmann; R Buchen; A Krolik; M Wiederholt
Journal:  Invest Ophthalmol Vis Sci       Date:  1982-05       Impact factor: 4.799

View more
  6 in total

1.  Prevention of experimental corneal allograft rejection in rabbits using cyclosporin-collagen shields.

Authors:  K Mahlberg; R J Uusitalo; B Gebhardt; H E Kaufman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

2.  Diclofenac sodium and cyclosporin A inhibit human lens epithelial cell proliferation in culture.

Authors:  P Cortina; M J Gómez-Lechón; A Navea; J L Menezo; M C Terencio; M Diaz-Llopis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-03       Impact factor: 3.117

3.  A compartmental model for the ocular pharmacokinetics of cyclosporine in rabbits.

Authors:  C Oh; B A Saville; Y L Cheng; D S Rootman
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

4.  Cyclosporin-A associated malignancy.

Authors:  Jonathan M Durnian; Rosalind M K Stewart; Richard Tatham; Mark Batterbury; Stephen B Kaye
Journal:  Clin Ophthalmol       Date:  2007-12

Review 5.  Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye.

Authors:  Diane D-S Tang-Liu; Andrew Acheampong
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

6.  Role of Multidrug Resistance Proteins in Nonresponders to Immunomodulatory Therapy for Noninfectious Uveitis.

Authors:  Ravichandra Tagirasa; Khokan Rana; Hrishikesh Kaza; Debaprasad Parai; Santhoshkumar Damera; Soumyava Basu
Journal:  Transl Vis Sci Technol       Date:  2020-04-18       Impact factor: 3.283

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.